ICH Q13 - Continuous Manufacturing of Drug Substances and Drug Products

What it says

Continuous manufacturing, where material is continuously fed into and product continuously removed from a manufacturing process, requires a control strategy addressing material traceability, real-time process monitoring, and diversion or rejection of nonconforming material, distinct from the batch-based control strategies traditionally used in pharmaceutical manufacturing.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Continuous manufacturing fundamentally changes what a batch even means, requiring a control strategy that can define batch boundaries within a continuous material stream and trace specific output back to the process conditions that produced it.
• Real-time process monitoring and control take on even greater importance in continuous manufacturing than in traditional batch processing, since the ability to divert or reject nonconforming material in real time is central to the control strategy's function.
• This is one of the newer ICH guidelines, reflecting continuous manufacturing's growing adoption, and connects closely to real time release testing concepts described in EU GMP Annex 17.

What inspectors look for

• Whether the control strategy clearly defines how batch boundaries are established within the continuous material stream and how traceability is maintained.
• Whether real-time monitoring and material diversion or rejection capability genuinely functions as designed, rather than existing only as a theoretical capability.
• Whether process validation for a continuous process adequately addresses startup, steady-state and shutdown conditions, which behave differently from a traditional discrete batch process.

Related regulations